Publications

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine
Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.
Journal of the National Cancer Institute 2017 Aug 28

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
Pinto LA, Dillner J, Beddows S, Unger ER
Vaccine 2018 Aug 6

Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges
Parker KH, Kemp TJ, Pan Y, Yang Z, Giuliano AR, Pinto LA
Vaccine 2018 May 3

Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies
Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, Schussler J, Gail MH, Safaeian M, Kemp TJ, Cortes B, Pinto LA, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group
Vaccine 2018 Aug 6

An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study
Beachler DC, Pinto LA, Kemp TJ, Nyitray AG, Hildesheim A, Viscidi R, Schussler J, Kreimer AR, Giuliano AR
Cancer, Epidemiology, Biomarkers, and Prevention 2018 Apr 27

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial
Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, Pan Y, Lazcano-Ponce E, Salmeron J, Giuliano AR
Journal of Infectious Diseases 2016 Oct 15

Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines
Matsui K, Adelsberger JW, Kemp TJ, Baseler MW, Ledgerwood JE, Pinto LA
PLOS One 2015 Sep 2

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials
Kreimer AR1, Struyf F2, Del Rosario-Raymundo MR3, Hildesheim A4, Skinner SR5, Wacholder S4, Garland SM6, Herrero R7, David MP2, Wheeler CM8; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.
Lancet Oncology 2015 Jul 16

A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays
Kemp TJ, Matsui K, Shelton G, Safaeian M, Pinto LA
Human Vaccines and Immunotherapeutics 2015 Feb 19

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay
Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M
Human Vaccines and Immunotherapeutics 2014 Oct 31

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus
Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.
BMC Infectious Diseases 2014 Mar 3

Comparison of antibody responses to human papillomavirus vaccination as measured by three assays
Robbins HA, Kemp TJ, Porras C, Rodriguez AC, Schiffman M, Wacholder S, Gonzalez P, Schiller J, Lowy D, Poncelet S, Esser M, Matys K, Hildesheim A, Pinto LA, Herrero R, Safaeian M
Frontiers in Oncology 2014 Jan 13

Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda
LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M
Vaccine 2014 Oct 29

Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus
Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE
Human Vaccines and Immunotherapeutics 2018 Nov 1

Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes
Alter BP, Giri N, Pan Y, Savage SA, Pinto LA
Vaccine 2014 Feb 26

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.
Cancer Prevention Research 2013 Nov 6

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial
Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA
Human Vaccines and Immunotherapetics 2013 Apr 9

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays
Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.
PLOS One 2013 Jan 2

Human papillomavirus vaccines--immune responses
Stanley M, Pinto LA, Trimble C
Vaccine 2012 Nov 20

Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials
Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, Esser M, Meuree A, Matys K, Quint W, van Doorn LJ, Sherman ME, Herrero R, Pinto LA, Hildesheim A
Cancer Epidemiology, Biomarkers, and Prevention 2012 Sep 21

Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels
Kemp TJ, Safaeian M, Miner S, Williams MC, Rodriguez AC, Herrero R, Hildesheim A, Pinto LA
Frontiers in Oncology 2012 Jun 25

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)
Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA
Vaccine 2012 Dec 17

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals
Dauner JG1, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA
Molecular and Cellular Probes 2012 Apr 26

Alterations of T-cell surface markers in older women with persistent human papillomavirus infection
Rodríguez AC, García-Piñeres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmella I, Ramírez M, Villegas M, Schiffman M, Burk R, Freer E, Bonilla J, Bratti C, Pinto LA
Infectious Causes of Cancer 2010 Nov 27

Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection
Kemp TJ, Hildesheim A, García-Piñeres A, Williams MC, Shearer GM, Rodriguez AC, Schiffman M, Burk R, Freer E, Bonilla J, Herrero R, Pinto LA
Cancer Epidemiology, Biomarkers, and Prevention 2010 Aug 19

Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years
González P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C, Wacholder S, Piñeres AG, Pinto LA, Burk RD, Herrero R
Cancer Epidemiology, Biomarkers, and Prevention 2010 Dec 19

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine
Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA
Vaccine 2010 Jul 26

Determinants and correlation of systemic and cervical concentrations of total IgA and IgG
Safaeian M, Kemp T, Falk RT, Rodriguez AC, Hildesheim A, Williams M, Porras C, Herrero R, Pinto LA
Cancer Edpidemiology, Biomarkers, and Prevention 2009 Oct 18

Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients
García-Piñeres AJ, Hildesheim A, Dodd L, Kemp TJ, Yang J, Fullmer B, Harro C, Lowy DR, Lempicki RA, Pinto LA.
The Journal of Immunology 2009 Feb 1

Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies
Kemp TJ, Hildesheim A, Falk RT, Schiller JT, Lowy DR, Rodriguez AC, Pinto LA
Clinical and Vaccine Immunology 2008 Jan 15

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA; Costa Rica Vaccine Trial (CVT) Group
Vaccine 2008 Jul 4

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA
Human Vaccines 2008 Dec 4

Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles
García-Piñeres A, Hildesheim A, Dodd L, Kemp TJ, Williams M, Harro C, Lowy DR, Schiller JT, Pinto LA
Clinical Vaccine Immunology 2007 Aug 14

Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27
Fakruddin JM, Lempicki RA, Gorelick RJ, Yang J, Adelsberger JW, Garcia-Pineres AJ, Pinto LA, Lane HC, Imamichi T
Blood 2007 Mar 1

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A
Virology 2006 Sep 30

DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies
García-Piñeres AJ, Hildesheim A, Williams M, Trivett M, Strobl S, Pinto LA
Journal of Immunological Methods 2006 Jun 30

Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine
García-Piñeres AJ1, Hildesheim A, Trivett M, Williams M, Wu L, Kewalramani VN, Pinto LA
European Journal of Immunology 2006 Feb 2

Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women
García-Piñeres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, Ramírez M, Villegas M, Schiffman M, Rodríguez AC, Burk RD, Hildesheim M, Freer E, Bonilla J, Bratti C, Berzofsky JA, Pinto LA
Cancer Research 2006 Nov 15

Fixation and cryopreservation of whole blood and isolated mononuclear cells: Influence of different procedures on lymphocyte subset analysis by flow cytometry
Pinto LA, Trivett MT, Wallace D, Higgins J, Baseler M, Terabe M, Belyakov IM, Berzofsky JA, Hildesheim A
Cytometry 2005 Jan 15

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood
Pinto LA, Castle PE, Roden RB, Harro CD, Lowy DR, Schiller JT, Wallace D, Williams M, Kopp W, Frazer IH, Berzofsky JA, Hildesheim A
Vaccine 2005 May 20

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles
Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A
Virology 2006 Sep 30

Immune profiling of plasma and cervical secretions using recycling immunoaffinity chromatography
Castle PE, Phillips TM, Hildesheim A, Herrero R, Bratti MC, Rodríguez AC, Morera LA, Pfeiffer R, Hutchinson ML, Pinto LA, Schiffman M
Cancer Epidemiology, Biomarkers, and Prevention 2003 Dec 12